

## RESEARCH ARTICLE

## Open Access



# A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries

Lorenzo Zammarchi<sup>1</sup>, Gianluigi Casadei<sup>2</sup>, Marianne Strohmeier<sup>1</sup>, Filippo Bartalesi<sup>3</sup>, Carola Liendo<sup>4</sup>, Alberto Matteelli<sup>5</sup>, Maurizio Bonati<sup>2</sup>, Eduardo Gotuzzo<sup>4</sup>, Alessandro Bartoloni<sup>1,3\*</sup> and the COHEMI project study group

## Abstract

**Background:** In low-incidence countries, most tuberculosis (TB) cases occur among migrants and are caused by reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin. Diagnosis and treatment of LTBI are rarely implemented to reduce the burden of TB in immigrants, partly because the cost-effectiveness profile of this intervention is uncertain.

The objective of this research is to perform a review of the literature to assess the cost-effectiveness of LTBI diagnosis and treatment strategies in migrants.

**Methods:** Scoping review of economic evaluations on LTBI screening strategies for migrants was carried out in Medline.

**Results:** Nine studies met the inclusion criteria. LTBI screening was cost-effective according to seven studies. Findings of four studies support interferon gamma release assay as the most cost-effective test for LTBI screening in migrants. Two studies found that LTBI screening is cost-effective only if carried out in immigrants who are contacts of active TB cases.

**Discussion and Conclusions:** Our findings support the cost-effectiveness of LTBI diagnostic and treatment strategies in migrants especially if they are focused on young subjects from high incidence countries. These strategies could represent an adjunctive and synergistic tool to achieve the ambitious aim of TB elimination.

## Background

In low incidence countries, the majority of the cases of active tuberculosis (TB) occur among migrants from high incidence countries [1]. In this setting migrants can develop TB following three main mechanisms [2]:

1. TB can already be present at the time they enter in the host country;

2. TB can be the consequence of the reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin, occurring months to years after the settlement in the host country [3, 4];
3. Primary progressive TB can follow a new infection acquired in the host country [4, 5] or during a return travel to the country of origin [6].

Most countries with low TB incidence adopt TB screening policies for migrants from high TB incidence countries. The majority of countries screen migrants for active TB through chest x-ray (CXR) before or soon after arrival, while screening for LTBI is not consistently implemented [7]. Screening protocols that include CXR as first

\* Correspondence: [alessandro.bartoloni@unifi.it](mailto:alessandro.bartoloni@unifi.it)

<sup>1</sup>Infectious Diseases Unit, Department of Experimental & Clinical Medicine, University of Florence School of Medicine, Largo Brambilla 3, 50134 Florence, Italy

<sup>3</sup>SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy

Full list of author information is available at the end of the article

step are able to identify the majority of migrants with active TB at entry and, occasionally, migrants with radiological alterations suggestive of LTBI. However, most persons with LTBI go undetected as a diagnostic test for this condition is not usually applied. Epidemiological studies based on molecular techniques to genotype the *M. tuberculosis* isolates showed that 55–90 % of TB cases diagnosed in foreign born patients are due to LTBI reactivation [8, 9].

Screening migrants for LTBI and providing treatment to those with this condition is a plausible strategy to prevent the disease and reduce the risk of spread infection in the native population [10, 11]. Diagnosis and treatment of LTBI was recommended in Europe already more than ten years ago [12, 13], and is now included among the main interventions of the new global post-2015 strategy for TB control [13].

Only 16 of 29 industrialized countries belonging to the Organization for Economic Co-operation and Development, screen immigrants for LTBI, most frequently post-arrival in the host country [7].

In 11 of these 16 countries, the screening is compulsory for legal migrants. Children and young adults (<40 years) are most commonly targeted for LTBI screening. The most common test used for screening is Tuberculin Skin Test (TST), used in 11 out of 16 countries. Patients and physicians compliance to the LTBI screening protocol is essential for the effectiveness [10], but it is reported to be low [11].

Appropriate information on cost-effectiveness of LTBI screening strategies may help the policy makers to decide appropriate interventions. Thus, we performed a review of published economic evaluations (EE) of different LTBI screening strategies.

## Methods

Ethical approval was not required for this review study.

### Inclusion criteria

In this review we included studies with all the three following criteria: 1) had migrants as study target population; 2) included diagnosis and treatment for LTBI; 3) reported findings of EE analyses. Both model-based EEs and those alongside clinical trials (or in combinations as well) were included.

### Search strategy

MEDLINE and the Cochrane Library electronic databases were searched for studies published up to July 2014. The terms used for the search strategy were: (latent tuberculosis OR LTBI OR “latent tuberculosis”[Mesh]) AND (screening OR Mantoux OR IGRA OR “mass screening”[Mesh] OR “tuberculin test”[Mesh] OR “Interferon-gamma Release Tests”[Mesh]) AND (cost-effect\* OR

cost-bene\* OR “Cost- Benefit Analysis”[Mesh]). No language restriction was done. The search was performed also using the term “latent tuberculosis screening in migrants” as free text.

### Data extraction and assessment

All references retrieved were collected using the EndNote®, version X5 (Thomson Reuter) program. Identified titles and abstracts were screened for their eligibility for inclusion and the full text of potentially relevant studies was obtained and examined. Two review authors (LZ, GC) independently screened titles and abstracts of each study. Based on the full text revision, the two reviewers independently selected the studies, and inter-reviewer disagreement was solved by discussion. The following information was extracted: setting, study design, participants, EEs data, including type of EE, screening alternatives, cost description, analysis perspective, source of data (literature, clinical studies), modeling (if any, including time horizon and discount rate), key results and authors’ conclusions. The following data were collected for clinical trials used for EE analyses: inclusion criteria, study participants, setting, design and methods, results and authors’ conclusions. Agreement on inclusion was calculated using the Kappa statistics.

Study quality was assessed using an established checklist of criteria for assessing the quality of economic evaluations in health care [14]. This tool includes ten items regarding cost effectiveness analysis: the presence of a clearly stated hypothesis and comparator; the used methods; the medical evidence; appropriate costs and benefits considered; a marginal analysis and a sensitivity analysis have been undertaken; the analysis was appropriate to the local environment.

## Results


### Search results

The literature search resulted in 109 titles. A total of 86 duplicates or non-pertinent or non-appropriate references were deleted, resulting in 23 potentially relevant studies. Reviewers agreed on 18 of 23 papers (78.3 %) selected for reliability check ( $K = 0.697$ ), and disagreements were resolved by consensus. Ten of 23 papers (43.5 %) met inclusion criteria and were therefore included in the final step of review (Fig. 1).

### General characteristics of included studies

The 10 research studies included in the review (Table 1) were published in 8 journals, 2 in the *Am J Respir Crit Care Med* and *Thorax*, and the others in 6 different journals. The distribution of papers per year of publication ranged from 2000 to 2014.

Four studies were performed in the US, 3 in the United Kingdom, and 3 in Canada.



In four studies age limitations in the study population were used: children 4 to 18 years old [17], migrants >16 year old (median 29 years) [16], migrants or foreign born subjects >18 year old [18], and migrants aging <35 years [15].

Four studies considered immigrants at the moment of their entrance or application for residence permission [11, 18–20]. Two studies referred to “new immigrants” or foreign born subjects without further specification [17, 21, 22]. Two studies referred to immigrants arrived within 5 years [7, 15]. One study considered both recent migrants and foreign born residents in US for more than 5 years [23].

In 5 studies the screening was carried out according to TB incidence in the country of origin regardless of age [11, 17, 19, 20, 23], whereas 3 studies compared the cost-effectiveness of screening migrants with different thresholds of TB incidence in the country of origin

[14, 16, 21]. One study considered migrants from all developing countries [18].

Several LTBI diagnostic strategies (screening with CXR and follow-up of inactive TB, screening with TST, screening with TST followed by confirmation with Interferon gamma release assay - IGRA, screening with single step IGRA) were compared with each other and/or with different non-LTBI screening strategies including no screening, screening for active TB with CXR, and close-contact investigation (Table 1). Isoniazid for 6–9 months was the LTBI treatment regimen used in the majority of studies [11, 17, 19, 20, 22, 23], in one study isoniazid plus rifampicin for 3 months was used [16], in one study either isoniazid for 6 months or isoniazid plus rifampicin for 3 months were used [15], and in one study different LTBI treatment regimens (isoniazid for 9 months, rifampicin for 4 months, rifampicin plus pyrazinamide for 2 months) were compared [18]. In one study the LTBI treatment regimen was not specified [21].

**Table 1** Economic evaluations of latent tuberculosis infection screenings published up to July 2014

Author (Country; Year)	Alternatives	Data source	EE Type	Perspective	Model Horizon Discount rate	Cost	Cost description	Differential Costs	ICER	Conclusion
Dasgupta et al. (Canada; 2000) [19]	1. Screening (medical evaluation, CXR); 2. Surveillance of inactive TB, including LTBI treatment; 3. Close-contact investigation	Administrative data bases	CEA	Health care payer	Markov 20 years	Direct	CXR, clinic visits, investigations, hospitalization, drugs, physicians' and pharmacists' fees, administrative activities.	<ul style="list-style-type: none"> <li>• TB case detected: CAN\$ 31,418; prevented: CAN\$ 73,125;</li> <li>• CAN\$ 55,728;</li> <li>• CAN\$ 155,729;</li> <li>• CAN\$ 10,275;</li> <li>• CAN\$ 29,668.</li> </ul>		Close-contact investigation was highly cost-effective and resulted in net savings. Immigrant applicant screening and surveillance programs had a significant impact but were much less cost-effective, in large part because of substantial operational problems. Radiographic screening of newly arriving foreign-born populations for TB could be cost-effective and have considerable individual and public health benefits.
Khan et al. (USA; 2002) [18]	1. No LTBI screening; 2. TST followed by INH; 3. TST followed by RIF; 4. TST followed by RIF plus PZM.	Data bases	CEA, CUA	Societal	Markov Lifetime 3.00%	Health Direct  Indirect	Transportation, ambulatory care, services of interpreters, laboratory tests, medications, adverse drug reactions, hospitalization, and patients' time.	<p>Total savings: US\$60 to US\$90 million, assuming to avert 9–10 thousand TB infections per year.</p>	CEA <ul style="list-style-type: none"> <li>• TST followed by INH: savings or dominated, depending on regions.</li> <li>• TST followed RIF: dominant.</li> <li>• TST followed RIF plus PZM: saving or cost-effective (US\$2,551 - US\$149,978 per future case averted), depending on regions.</li> </ul> <p>per QALY</p> <ul style="list-style-type: none"> <li>• TST followed by INH: savings, US\$914 - US\$5,952, or dominated depending on regions.</li> <li>• TST followed by RIF: dominant.</li> <li>• TST followed by RIF plus PZM: savings, or US\$1,276 - US\$53,388, depending on regions.</li> </ul>	<p>Results variable according to country of origin.</p> <p>A strategy of detecting and treating LTBI was cost-saving among immigrants from Mexico, Haiti, sub-Saharan Africa, South Asia, and developing nations in East Asia and the Pacific.</p> <p>Screening was highly cost-effective among immigrants from other developing nations. RIF-PZM was the preferred treatment for treating LTBI in immigrants from Vietnam, Haiti, and the Philippines.</p>

**Table 1** Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)

Brassard et al. (Canada; 2006) [17]	1. LTBI school-screening program in newly arrived immigrant children (TST followed by INH); 2. Active TB management through passive case finding.	Clinical trial <sup>c</sup>	CBA	Health care payer	No	Health Direct	Total material and labor costs associated with the school-screening program and the associate investigations for children and associates.	Total savings: CAN\$ 363,923. Without associate investigation: CAN\$ 268,393.		The school-based LTBI-screening program was found to be cost-effective.  Savings were mainly due to hospitalization costs.
Porco et al. (USA; 2006) [20]	1. Follow-up of TB-notification patients, including LTBI treatment for latently infected individuals; 2. No follow-up.	Published literature, administrative data bases	CEA, CUA	Health care payer	Markov 20 years 3.00%	Direct	Diagnostic tests, nursing assessments and doctor visits, drugs, side effects, hospitalizations.	The program yielded 7.7 net QALYs, US\$ 25,000 in net savings, and prevented 4 cases of TB.	Treatment of TB4s was cost-saving.  Treatment of TB2s was highly cost-effective: US\$4,400 per QALY and US\$4,700 per case prevented.	Domestic follow up is highly cost-effective as early detection and treatment reduces the rate of hospitalization.
Oxlade O et al. (Canada;2007) [11]	1. CXR; 2. TST; 3. QFT; 4. TST+QTF; 5. No screening.  Three scenarios: a) immigration entry screening; b) close or c) casual contacts.	Published literature, administrative data bases	CEA	Societal	Markov 20 years 3.00%	Health Direct	All government and health system costs, patients' out-of-pocket expenditures, but not TB-related death or disability.	Savings only in high-very high risk populations:  • CXR - CAN\$ 44,710; CAN\$ 65,490;  • TST - CAN\$ 136260; CAN\$ 476320;  • QFT - CAN\$ 100,490; CAN\$ 440,550.	CXR - the least costly ICER per case prevented: CAN\$ 875 for immigrants from high-incidence TB up to CAN\$ 2.2 million from low incidence.  QFT - the most expensive: CAN\$62,643 up to CAN\$1,122,200.  TST - better than QFT with saving up to CAN\$35,000 compared to QFT, but in populations BCG-vaccinated after infancy, where TST more expensive because of low specificity.	Screening with CXR would be the most and QFT the least cost-effective.  Screening for LTBI, with TST or QFT, is cost-effective only if the risk of disease is high. The most cost-effective use of QFT is to test TST-positive persons.  Screening with TST or QFT was much more cost-effective in contacts than entering immigrants.  However, the selection of screening strategy is less important than program performance. Programs considering these new <i>ex vivo</i> tests for LTBI should thus first ensure that a high proportion of those with positive tests will be medically evaluated, prescribed and complete therapy.

**Table 1** Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)

Author (Year)	Study Design	Setting	Health Care Payer	Model	Health Direct	Intervention	Cost per case identified	Cost per case identified	Notes
Hardy et al. (UK; 2010) [21]	1. NICE guidance 2006; 2. Leeds protocol: QTF first in immigrants from countries with TB incidence >200/10 <sup>5</sup> followed by CXR (all ages, but mean age was 30.8 year).	Clinical trial <sup>c</sup>	CEA	Health care payer	No	Health Direct	Cost per case LTBI identified	Cost per case identified: • NICE protocol: £160.81; • Leed protocol: £93.16.	QFT-first protocol can be carried out more cheaply than a CXR-first protocol, with a cost-saving of about 35% (£67.65) compared to NICE protocol. This saving is due to the reduced number of CXRs required.
Linan et al. (USA; 2011) [23]	1. TST; 2. IGRA; 3. No LTBI screening. Risk-groups <sup>a</sup>	Published literature	CEA, CUA	Health care payer	Markov Lifetime 3.00%	Health Direct	Nursing and physician visits, diagnostic tests, medications, hospitalizations, contact tracing, and directly observed therapy.	<ul style="list-style-type: none"> <li>• Individuals at highest risk of TB reactivation (close contacts and HIV-infected) - ICER of IGRA compared to TST was &lt;\$100,000/ QALY gained.</li> <li>• The foreign-born - IGRA was cost-saving compared to TST and cost-effective compared to no screening (ICER &lt;\$100,000/ QALY gained).</li> <li>• Vulnerable populations (homeless, drug user, former prisoner) - ICER of TST screening was approximately \$100,000-\$150,000/ QALY gained, but IGRA was not cost-effective.</li> <li>• Medical co-morbidities (diabetes and others) - ICER of screening with TST or IGRA was &gt;\$100,000/QALY.</li> </ul>	In foreign-born subjects IGRA was cost-saving compared to TST and cost-effective compared to no screening.

**Table 1** Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)

Pareek et al. (UK; 2011) [15]	1. QFT; 2. NICE guidance 2006 <sup>b</sup> .	Clinical trial <sup>c</sup>	CEA	Government health care payer	Markov 20 years 3.50%	Direct	UK NICE TB guidelines	Screening of immigrants from any countries irrespective of tuberculosis incidence would cost:  • QFT more than £1.5 million and prevent 44.5 cases of tuberculosis;  • NICE guidance ≈£850,000 and prevent 13.2 cases.	• Screen immigrants aged 16–35 years from countries with incidences/10 <sup>5</sup>  ≥250/10 <sup>5</sup> : £ 17,956 per case averted; ≥ 150/10 <sup>5</sup> : £ 20,819; ≥40/10 <sup>5</sup> : £ 29,403.  Screen immigrants aged ≤35 years irrespective of TB incidence: £ 101,938.	Screening for latent infection can be implemented cost-effectively at a level of incidence that identifies most immigrants with latent tuberculosis, thereby preventing substantial numbers of future cases of active tuberculosis.
Pareek et al. (UK; 2012) [16]	1. TST+ in <35y old immigrants; 2. QTF+ in <35y old immigrants; 3. T-SPOT+ in <35y old immigrants.  All with or without CXR port of entry.	Clinical trial <sup>c</sup>	CEA	Government health care payer	Markov 20 years	Direct	Current UK national guidance associated with additional costs of between £594,957 and £1,530,303 over 20 years.	• QFN (single): £21,565 - £34,754 per TB case averted.  • CXR plus single QFN: £59,489.  • CXR plus single T.SPOT.TB: £402,422.	Mandatory CXR on arrival could be safely eliminated in order to improve screening cost-effectiveness with single-step QTF at incidence threshold >250/10 <sup>5</sup> per year.	
Iqbal et al. (USA, 2014) [22]	1. QFT; 2. TST.	Administrative data base (2007)	CEA	Government health care payer	Decision model	Health Direct	Screening, CXR, Treatments, lab tests and diagnostics, physicians' and staff time.  Total screening cost: TST US\$38; QFT-G US\$74  Key assumption. False positive rates: • U.S. born TST 66%; QFT 40% Treatment duration: 9 months • Foreign born TST 69%; QFT 18% Treatment duration: 9 months	Differential costs for screening and follow-up for subjects who were estimated to be test positive on 1,000 latent TB infections  • U.S. born QFT: +US\$25,037 vs. TST.  • Foreign born QFT: –US\$135,946.	QFT is cost-effective especially for high-risk populations such as foreign-born individuals.	

EE economic evaluation, ICER Incremental cost-effectiveness ratio, CEA cost-effectiveness analysis, CXR chest X-ray, CAN\$ Canadian dollar, INH isoniazid, RIF rifampicin, PZM pyrazinamide, CUA cost-utility analysis, US\$ United States dollar, TST tuberculin skin test, QTF Quantiferon, QALY Quality Adjusted Life Years, CBA cost-benefit analysis, LTBI latent tuberculosis infection, TB tuberculosis, NICE National Institute for Health and Care Excellence, TB2 subjects with evidence of infection but no evidence of disease, TB4 subjects with stable radiographic abnormalities suggestive of TB together with evidence of TB infection and negative bacteriologic studies

a) Risk groups including recent immigrant adults and children, foreign-born residents living in the U.S. for more than five years (stratified by age), close contact adults and children, HIV-infected individuals, the homeless, injection drug users, former prisoners, gastrectomy patients, underweight patients, and persons with silicosis, diabetes, and end-stage renal disease.

b) CXR in all immigrants from countries with TB incidence >40/10<sup>5</sup> and >16yo; TST if <16yo or <35yo from Sub Saharan Africa or from countries >500/10<sup>5</sup>; QTF in TST positive to confirm LTBI.

c) Clinical trial description reported as Additional file 1: Table S2

All evaluations complied with the following quality criteria: presence of a clear hypothesis, methodology, selection of comparators, choice of appropriate benefits, and local applicability. Only four evaluations referred to clinical trials [15–17, 21], while medical evidence was derived from published literature in the remaining 6 studies. Appropriate direct and indirect health costs were considered in 8 assessments and sensitivity analysis was performed in seven evaluations. The lower quality study was the oldest [19]. Additional file 1: Table S1 presents different assumptions concerning progression rate and sensitivity as well as specificity of the TST and IGRAs applied in the different papers.

### Economic evaluations of included studies

Cost-effectiveness analyses (CEA) were conducted in all EEs, and only one cost-benefit analysis (CBA) [16]. Cost-utility analysis (CUA) was performed in addition to CEA in three EEs [18, 20, 23]. EEs were conducted under the perspective of public health payer. Direct health costs were assessed in all studies while indirect costs were considered in one study [18]. As shown in Additional file 1: Table S2, four EEs were based on the results of specific studies while the remaining 6 assessments were based on available data in literature. Three studies [17, 20, 23] were carried out prospectively for 12 to 31 months. Decision modeling was adopted in 8 EEs with a time horizon up to 20 years [11, 15, 16, 19, 20] or lifetime [18, 23]. Data were collected from studies carried out *ad hoc* in two EEs [20], while models were fed with data publicly available in the remaining 6 EEs.

Screening for LTBI in migrants was cost-effective according to 8 studies [15–18, 20–23] and cost-saving according the selected scenarios in 3 of these studies [17, 18, 20]. In 5 out of 8 studies in which LTBI screening of migrants was cost-effective, a comparison between single step IGRA and TST or TST plus confirmatory IGRA was carried out [15, 16, 22–24]. In all 5 studies one step IGRA was the most cost-effective strategy (Quantiferon®, QTF in 4 studies [15, 16, 21, 22] and an unspecified IGRA in the remaining study [23]). In the 2 studies in which LTBI screening strategy was not cost-effective (dominated), the dominant strategies were contact tracing investigations in one case [17], and screening for active TB with CXR in the other case [11].

One article found that screening for LTBI with a single step IGRA was cost-effective regardless of time since immigration [23], while in other studies the cost-effectiveness was evaluated in recent migrants only.

One study compared the cost-effectiveness of screening stratified by age and showed that screening was more cost-effective when addressing recent immigrant adults than children and that screening of US foreign-born residents aged less than 45 years was more cost-effective than

screening of foreign-born residents aged 45–64 years [23]. In this study patient age affected cost-effectiveness results through its impact on the lifetime risk of reactivation. In 3 other studies, in which LTBI screening was cost-effective, the analysis was limited to children [17], or young adults [15, 16].

Three studies compared the cost-effectiveness of screening at different thresholds of TB incidence in the country of origin. According to one study, the highest cost-effectiveness was reached by screening immigrants from countries with TB incidence above 200/100,000 while for two other studies, the threshold was 250/100,000 [15, 16, 21].

One article provided information on which LTBI treatment regimen (among isoniazid for 9 months, rifampicin for 4 months or rifampicin plus pyrazinamide for 2 months) would be more cost-effective according to migrants country of origin showing that pyrazinamide plus rifampicin for 2 months would be the most cost-effective treatment for migrants from Vietnam, Philippines, and Haiti, while isoniazid would be the most advantageous regimen for other migrants [18].

### Discussion

According to the majority of studies included in this review, at least three important elements can be underlined. First, screening programs for detecting and treating LTBI in immigrants lead to substantial health and economic benefits under a societal perspective. Second, a one-step IGRA-protocol is the most cost-effective strategy for LTBI screening in migrants. Third, targeting young migrants from countries at higher incidence of TB increases the cost-effectiveness of screening.

Limitations and possible biases should be considered. First, our review, even if performed in a systematic methodology, did not respect all the criteria for systematic reviews (for example we consulted only two electronic database) so we cannot make strong and quantitative conclusions. Secondly, we don't know whether the LTBI screening strategy that seems more cost-effective according to the majority of the selected studies (the use of IGRA) would be cost-effective in all context/jurisdiction, as this heavily depends on the country-specific treatment procedures and costs. Furthermore, we don't have the quality or quantitative weights of each study to be able to make a pooled conclusion on cost-effectiveness. All these issues can potentially be solved in a meta-analysis, that is not attempted in this review given the high inhomogeneities among the different studies included.

Additionally, all the selected studies included in the review were carried out in countries where a CXR at entry is currently performed for active TB screening of newly arrived migrants. Most of the papers aimed at defining cost-effectiveness of adding screening for LTBI to the



ongoing CXR-based screening for active TB [15, 18–21, 23]. The cost-effectiveness of LTBI screening of migrants population should also be evaluated in other low endemic countries.

While most of the studies found that screening programs for detecting and treating LTBI lead to substantial health and economic benefits under a societal perspective, other studies reached opposite conclusions. The importance of how methodological differences affect results of EEs has been recently demonstrated in a systematic review on methodological aspects of cost-effective analysis of IGRAs for the diagnosis of LTBI [24]. According to this study, some of the most relevant contributing factors generating different conclusions are the study inputs selection, the inconsistencies in the costing approach, the utility of the QALY (Quality Adjusted Life Year) as the effectiveness outcome, and the manner in which authors choose to present and interpret study results.

Among the studies selected in our review, Oxlade O et al. state that screening for active TB with CXR would be the most cost-effective and QFT the least cost-effective for screening of migrants on arrival [11], while Pareek M et al. concluded that mandatory CXR on arrival could be safely eliminated in order to improve screening cost-effectiveness with single-step IGRA [16]. Opposite conclusions were reached because Oxlade O et al. assumed a very low prevalence of LTBI in arriving immigrants (0.08–2.1 %) [11], while Pareek M et al. assumed a high rate of LTBI treatment completion (85 % in case base scenario) [16].

Studies performed under program conditions have shown that completion of LTBI treatment could be much lower than what was assumed in the study published by Pareek M et al. [16] with a better trend observed when shorter and unsupervised regimen are used [25]. It will be interesting to evaluate the completion rate and cost-effectiveness of shorter regimen such as weekly-administered rifapentine plus isoniazid for three months [26, 27] in migrants.

In migrants the diagnostic delay in cases of active TB is mainly related to the delayed presentation of the patients to the health system [28, 29] and it is responsible for the spread of the disease among other members of their community. Contact investigation should therefore be strengthened in migrants, as well as in the general population [30]. However, as assumed by the majority of economic models reviewed, screening and treatment for LTBI in migrants would prevent active TB cases and solve the problem at its roots.

The reliability of Markov models, where time horizons of 20 years or life time were used, may be matter of concern. In fact, in most cases, modeling was based on published or retrospective data while the prospective trials

supporting three EEs were all open label and only one was controlled. The actual epidemiological data shows that the global TB burden is reducing, though at a slow pace, at global level [31], and in industrialized countries, particularly among native populations [32]. In this scenario, while the yield of the screening for LTBI will decrease over time, however the contribution to the reduction of incidence by diagnosis and treatment of LTBI will progressively increase.

Growing consensus indicates that progress in TB control in the low- and middle-income world will require not only investment in strengthening TB control programs, diagnostics, and treatment but also action on the social determinants of the disease [33]. To reduce the incidence of TB, the drivers of the epidemic and social determinants of TB need to be addressed. These include co-morbidities, substance use, the social and economic conditions that determine both the course of the TB epidemic and exposure to these risk factors [34]. This is probably true for control of TB in migrants that often live in disadvantaged socio-economic conditions in the host country with an increased risk of both, to reactivate LTBI or to acquire a new infection. In this perspective LTBI screening and treatment in migrants could represent a synergistic tool to achieve the ambitious aim of TB elimination.

## Conclusions

The majority of the studies support the use of LTBI screening strategies in migrants based on their cost-effectiveness findings. When LTBI screening for migrants are implemented they should focus especially on young migrants from high incidence countries and effort should be done to maximize the adherence to LTBI treatment. In this view shorter LTBI treatment regimen are preferred. Based on our review of EE analysis studies, the use of one step IGRA is the best option in this particular setting. These findings should be confirmed by a cost-effectiveness evaluation based on a medium-term prospective study.

LTBI should be well integrated among the TB control program for migrants and must be part of a wider approach with the aim of facilitating access of migrants to the national health system, re-orienting health services, improving the adherence to anti-tuberculosis treatment in cases of active TB, and promoting early diagnosis of active TB cases by primary care health operators [35].

## Additional file

**Additional file 1: Table S1.** Different assumptions concerning progression rate and sensitivity as well as specificity of the TST and IGRAs applied in the different papers. **Table S2.** Clinical trials referring to economic evaluations. (DOCX 22 kb)

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

Conceived and designed the study: AB, FB, EG, MB. Performed the study: LZ, GC, MS, CL. Analyzed the data: LZ, GC, MB. Wrote the paper: LZ, GC, MB, AM, AB. All authors read and approved the final manuscript.

**Authors' information**

Not applicable.

**Acknowledgments**

Authors thank the COHEMI (COordinating resources to assess and improve HEalth status of Migrants from Latin America)-project study group that includes: Maurizio Bonati<sup>a</sup>, Chiara Pandolfini<sup>a</sup>, Francesca Severino<sup>a</sup>, Valeria Confalonieri<sup>a</sup>, Gianni Tognoni<sup>a</sup>, Zeno Bisoffi<sup>b</sup>, Dora Buonfrate<sup>b</sup>, Andrea Angheloni<sup>b</sup>, Marco Albonico<sup>b,c</sup>, Alessandro Bartoloni<sup>d</sup>, Marianne Strohmeyer<sup>d</sup>, Lorenzo Zammarchi<sup>e</sup>, Filippo Bartalesi<sup>e</sup>, Jose Muñoz<sup>f</sup>, Ana Requena-Mendez<sup>f</sup>, Maria Roura<sup>f</sup>, Laia Ventura<sup>f</sup>, Robert Pool<sup>g</sup>, Christopher Pell<sup>g</sup>, Anita Hardon<sup>g</sup>, Peter Chiodini<sup>h</sup>, Juan Moreira<sup>k</sup>, Mariella Anselmi<sup>k</sup>, Roberto Sempértegui<sup>k</sup>, Eduardo Gotuzzo<sup>l</sup>, Maria Alejandra Mena<sup>l</sup>, Carola Liendo<sup>l</sup>, Héctor H. García<sup>m</sup>, Javier Bustos<sup>m</sup>, Saul Santivañez<sup>m</sup>, Faustino Torrico<sup>n</sup>, Daniel Lozano<sup>n</sup>, Teresa Hinojosa Cabrera<sup>o</sup>, Javier Ochoa Morón<sup>o</sup>, Ignacio AbaporiCuellar<sup>o</sup>, Jaime Amorós Suárez<sup>o</sup>, Guido ChumirayRojas<sup>o</sup>, Alessandra Nicoletti<sup>p</sup>, Elisa Bruno<sup>p</sup>.

a) Department of Public Health, Laboratory for Mother and Child Health, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

b) Centre for Tropical Diseases, SacroCuore-Don Calabria Hospital, Negrar, Verona, Italy.

c) Ivo de Carneri Foundation, Milano, Italy.

d) Infectious Disease Unit, Department of Experimental & Clinical Medicine, University of Florence School of Medicine, Florence, Italy.

e) SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

f) Servicio de Medicina Tropical y Salud Internacional, Centre de Recerca en Salut Internacional de Barcelona, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain

g) Centre for Social Science and Global Health, University of Amsterdam, The Netherlands.

j) Hospital for Tropical Diseases and London School of Hygiene & Tropical Medicine, London, United Kingdom.

k) Centre for Community Epidemiology and Tropical Medicine, Esmeraldas, Ecuador.

l) Instituto de Medicina Tropical Alexander von Humboldt, Universidad Cayetano Heredia, Lima, Peru.

m) Cysticercosis Unit, Instituto de Ciencias Neurológicas, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru.

n) Colectivo de Estudios Aplicados y Desarrollo Social, Cochabamba, Bolivia.

o) Taller de Educación y Comunicación TEKO-GUARANI, Camiri, Bolivia.

p) Dipartimento G.F. Ingrassia Sezione di Neuroscienze, Università di Catania, Catania, Italy.

**Availability of data and materials**

Not applicable.

**Funding source**

This work has been supported by the European Commission within the 7th Framework Programme under the COHEMI (COordinating resources to assess and improve HEalth status of Migrants from Latin America)-project - grant agreement no. FP7-GA-261495.

**Author details**

<sup>1</sup>Infectious Diseases Unit, Department of Experimental & Clinical Medicine, University of Florence School of Medicine, Largo Brambilla 3, 50134 Florence, Italy. <sup>2</sup>Laboratory for Mother and Child Health, Department of Public Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156 Milan, Italy. <sup>3</sup>SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy. <sup>4</sup>Instituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Barrios Altos, Lima, Peru. <sup>5</sup>Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB Co-infection and TB Elimination, University of Brescia, Brescia, Italy.

Received: 16 November 2014 Accepted: 7 September 2015

Published online: 24 September 2015

**References**

- European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. 2012.
- Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. *Eur Respir J*. 2009;34(5):1180–9.
- Codecasa LR, Porretta AD, Gori A, Franzetti F, Degli Esposti A, Lizioli A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993–1996. *Int J Tuberc Lung Dis*. 1999;3(7):589–95.
- Lillebaek T, Andersen AB, Bauer J, Dirksen A, Glismann S, de Haas P, et al. Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas. *J Clin Microbiol*. 2001;39(3):855–61.
- Diel R, Rusch-Gerdes S, Niemann S. Molecular epidemiology of tuberculosis among immigrants in Hamburg, Germany. *J Clin Microbiol*. 2004;42(7):2952–60.
- Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. *Am J Respir Crit Care Med*. 1998;158(6):1871–5.
- Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. *Emerg Infect Dis*. 2012;18(9):1422–9.
- Franzetti F, Codecasa L, Matteelli A, Degli Esposti A, Bandera A, Lacchini C, et al. Genotyping analyses of tuberculosis transmission among immigrant residents in Italy. *Clin Microbiol Infect*. 2010;16(8):1149–54.
- Hernandez-Garduno E, Kunimoto D, Wang L, Rodrigues M, Elwood RK, Black W, et al. Predictors of clustering of tuberculosis in Greater Vancouver: a molecular epidemiologic study. *CMAJ*. 2002;167(4):349–52.
- Alvarez GG, Gushulak B, Abu Rumman K, Altpeter E, Chemtob D, Douglas P, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. *BMC Infect Dis*. 2011;11:3.
- Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. *Int J Tuberc Lung Dis*. 2007;11(1):16–26.
- Broekmans J, Migliori G, Rieder H, Lees J, Ruutu P, Loddenkemper R, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. *Eur Respir J*. 2002;19(4):765–75.
- World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2014. EB134R4.
- Haycox A, Walley T. Pharmacoeconomics: evaluating the evaluators. *Br J Clin Pharmacol*. 1997;43:451–6.
- Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. *Lancet Infect Dis*. 2011;11(6):435–44.
- Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, Lalvani A, Kon OM. Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: observational study and economic analysis. *Thorax*. 2013 Mar;68(3):230–9. doi:10.1136/thoraxjnl-2011-201542. Epub 2012.
- Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. *Pediatrics*. 2006;117(2):e148–56.
- Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. *N Engl J Med*. 2002;347(23):1850–9.
- Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. *Am J Respir Crit Care Med*. 2000;162(6):2079–86.
- Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. *BMC Public Health*. 2006;6:157.

21. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. *Thorax*. 2010;65(2):178–80.
22. Iqbal AZ, Leighton J, Anthony J, Knaup RC, Peters EB, Bailey TC. Cost-effectiveness of using QuantiFERon Gold (QFT-G)(R) versus tuberculin skin test (TST) among U.S. and foreign born populations at a public health department clinic with a low prevalence of tuberculosis. *Public Health Nurs (Boston, Mass)*. 2014;31(2):144–52.
23. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. *Am J Respir Crit Care Med*. 2011;184(5):590–601.
24. Oxlade O, Pinto M, Trajman A, Menzies D. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. *PLoS One*. 2013;8(3), e56044.
25. Matteelli A, Casalini C, Raviglione MC, El-Hamad I, Scolari C, Bombana E, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. *Am J Respir Crit Care Med*. 2000;162(5):1653–5.
26. Sterling T, Munsiff SS, Frieden TR. Management of latent tuberculosis infection in immigrants. *N Engl J Med*. 2003;348(13):1289–92. author reply 1289–1292.
27. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculosis infection in the United States. *Int J Tuberc Lung Dis*. 2013;17(12):1531–7.
28. Gagliotti C, Resi D, Moro ML. Delay in the treatment of pulmonary TB in a changing demographic scenario. *Int J Tuberc Lung Dis*. 2006;10(3):305–9.
29. Mor Z, Kolb H, Lidji M, Migliori G, Leventhal A. Tuberculosis diagnostic delay and therapy outcomes of nonnational migrants in Tel Aviv, 1998–2008. *Euro Surveill*. 2013;18(12). pii: 20433.
30. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. *Eur Respir J*. 2013;41(1):140–56.
31. World Health Organization. Global tuberculosis control 2011. 2011.
32. European Centre for Disease Control and Prevention, World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. In: Surveillance report. Stockholm: European Centre for Disease Control and Prevention; 2012. p. 73–97.
33. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JD. The social determinants of tuberculosis: from evidence to action. *Am J Public Health*. 2011;101(4):654–62.
34. Rasanathan K, Sivasankara Kurup A, Jaramillo E, Lonnroth K. The social determinants of health: key to global tuberculosis control. *Int J Tuberc Lung Dis*. 2011;15 Suppl 2:S30–6.
35. Ministero della Salute. Aggiornamento delle raccomandazioni per le attività di controllo della tubercolosi. "Politiche efficaci a contrastare la tubercolosi nella popolazione immigrata". 2010.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

